Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
et al., Кардиология, doi:10.18087/cardio.2020.11.n1440
, Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for.., Кардиология, doi:10.18087/cardio.2020.11.n1440
Prospective 103 PCR+ patients in Russia, 33 treated with bromexhine+spironolactone, showing lower PCR+ at day 10 or hospitalization >10 days with treatment. Bromhexine 8mg 4 times daily, spironolactone 25-50 mg/day for 10 days.
This study includes bromhexine and spironolactone.
|
relative SHOKS-COVID score, 11.3% better, RR 0.89, p = 0.47, treatment mean 2.12 (±1.39) n=33, control mean 2.39 (±1.59) n=33.
|
|
risk of PCR+ on day 10 or hospitalization >10 days, 38.8% lower, RR 0.61, p = 0.02, treatment 14 of 24 (58.3%), control 20 of 21 (95.2%), NNT 2.7, odds ratio converted to relative risk.
|
|
hospitalization time, 8.2% lower, relative time 0.92, p = 0.35, treatment 33, control 33.
|
|
risk of no viral clearance, 87.4% lower, RR 0.13, p = 0.08, treatment 0 of 17 (0.0%), control 3 of 13 (23.1%), NNT 4.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mareev et al., 3 Dec 2020, Randomized Controlled Trial, Russia, peer-reviewed, 20 authors, this trial uses multiple treatments in the treatment arm (combined with bromhexine) - results of individual treatments may vary.
Abstract: §
EDITORIAL ARTICLES
Mareev V. Yu.1,2, Orlova Ya.A.1,2, Plisyk A.G.1,2, Pavlikova E.P.1,2, Matskeplishvili S.Т.1,
Akopyan Z.A.1,2, Seredenina E. M.1,2, Potapenko A. V.1,2, Agapov M.A.1,2, Asratyan D.A.1,
Dyachuk L.I.1,2, Samokhodskaya L. M.1,2, Mershina Е. А.1,2, Sinitsyn V. E.1,2, Pakhomov P. V.2,
Bulanova M.M.2, Fuks A.A.2, Mareev Yu.V.3,4, Begrambekova Yu. L.1,2, Kamalov А. А.1,2
Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
Faculty of Fundamental Medicine, Lomonosov Moscow State University, Russia
3
National Medical Research Centre for Therapy and Preventive Medicine Moscow, Russia
4
Robertson Centre for Biostatistics, Glasgow, Great Britain
1
2
Results of Open-Label non-Randomized Comparative
Clinical Trial: “BromhexIne and Spironolactone for
CoronаvirUs Infection requiring hospiTalization (BISCUIT)
Late treatment
is less effective
is less effective
mareev
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.